Trial of Eribulin Followed by Doxorubicin & Cyclophosphamide for Her2-negative, Locally Advanced Breast Cancer
Status:
Terminated
Trial end date:
2015-06-01
Target enrollment:
Participant gender:
Summary
Previous studies have shown that chemotherapy has the same effect on treating breast cancer
whether you receive it before or after surgery. Receiving chemotherapy before surgery, rather
than after surgery, may allow the patient to have less extensive surgery. The purpose of this
study is to identify new treatment regimens with better response rates and to find out if the
combination of eribulin followed by doxorubicin and cyclophosphamide can shrink the size of
the patient's breast tumor and allow you to preserve your breast. Additionally, by receiving
chemotherapy before surgery, the investigators will be able to determine if your cancer is
responsive to chemotherapy.